<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="ff3c9070-c458-4917-97a8-39c11edddd36"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <effectiveTime value="20091130"/>
   <setId root="6ca2803e-a4d6-4e57-a910-13237c93a4ce"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="194123980" root="1.3.6.1.4.1.519.1"/>
            <name>Physicians Total Care, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194123980" root="1.3.6.1.4.1.519.1"/>
                        <name>Physicians Total Care, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="relabel"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="f8d03ee1-d414-48f8-90fc-ba5c9054c343"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL listing data elements section"/>
               <effectiveTime value="20091130"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54868-5890" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MOVIPREP<suffix/>
                        </name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE,  SODIUM ASCORBATE and ASCORBIC ACID</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="65649-201" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1">
                                 <translation code="C48504" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5890-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43186" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CONTAINER"/>
                           </containerPackagedProduct>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="2" unit="L"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="54868-5890" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>POUCH A<suffix/>
                              </name>
                              <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>POLYETHYLENE GLYCOL 3350,SODIUM SULFATE,ANHYDROUS,SODIUM CHLORIDE,POTASSIUM CHLORIDE</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="100" unit="g"/>
                                    <denominator value="1" unit="L"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 3350</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>POLYETHYLENE GLYCOL 3350</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="7.5" unit="g"/>
                                    <denominator value="1" unit="L"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="0YPR65R21J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM SULFATE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="LYR4M0NH37" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>SODIUM CATION</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="2.69" unit="g"/>
                                    <denominator value="1" unit="L"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CHLORIDE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="LYR4M0NH37" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>SODIUM CATION</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="1.015" unit="g"/>
                                    <denominator value="1" unit="L"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CHLORIDE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>POTASSIUM CATION</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="Z0H242BBR1" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ASPARTAME</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="24RS0A988O" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEMON</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="L"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                 </containerPackagedProduct>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20080530"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA021881" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="2" unit="L"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="54868-5890" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>POUCH B<suffix/>
                              </name>
                              <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>ASCORBIC ACID, SODIUM ASCORBATE</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="4.7" unit="g"/>
                                    <denominator value="1" unit="L"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="PQ6CK8PD0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ASCORBIC ACID</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="PQ6CK8PD0R" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ASCORBIC ACID</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="5.9" unit="g"/>
                                    <denominator value="1" unit="L"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="S033EH8359" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM ASCORBATE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="LYR4M0NH37" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>SODIUM CATION</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="23OV73Q5G9" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ACESULFAME POTASSIUM</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="L"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                 </containerPackagedProduct>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20080530"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA021881" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20080530"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021881" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="137e29ac-49cb-43e3-bff4-2661748978d6"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>MoviPrep® is indicated for cleansing of the colon as a preparation for 
colonoscopy in adults 18 years of age or older.</paragraph>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="54a37dcb-3d4e-4441-971d-b7f1791f206a"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The MoviPrep dose for colon cleansing for adult patients is 2 
liters (approximately 64 ounces) of MoviPrep solution (with 1 additional liter 
of clear fluids) taken orally prior to the colonoscopy in one of the following 
ways:</paragraph>
                  <br/>
                  <list listType="ordered" ID="idbf0dedf-1003-4d46-8941-999e8f30d9e3">
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">Split-dose MoviPrep 
regimen:</content>
                        </content>  The evening before the colonoscopy, take the first liter 
of MoviPrep solution over one hour (one 8 ounce glass every 15 minutes) and then 
drink 0.5 liters (approximately 16 ounces) of clear fluid.  Then, on the morning 
of the colonoscopy, take the second liter of MoviPrep solution over one hour and 
then drink 0.5 liters of clear liquid at least one hour prior to the start of 
the colonoscopy; or 
</item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">Evening only (Full-dose) MoviPrep 
regimen:</content>
                        </content>  Around 6 PM in the evening before the colonoscopy, take 
the first liter of MoviPrep solution over one hour (one 8 ounce glass every 15 
minutes) and then about 1.5 hours later take the second liter of MoviPrep 
solution over one hour.  In addition, take 1 liter (approximately 32 ounces) of 
additional clear liquid during the evening before the colonoscopy. 
</item>
                  </list>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="emphasis">Preparation of the MoviPrep 
solution:</content>
                     </content>
                  </paragraph>
                  <paragraph>MoviPrep solution is prepared by emptying the contents of 1 pouch A and 1 
pouch B into a suitable glass container (or the container provided) and adding 
to the container 1 liter of lukewarm water.  Mix the solution to ensure that the 
ingredients are completely dissolved.  If the patient prefers, the MoviPrep 
solution can be refrigerated prior to drinking. The reconstituted solution 
should be used within 24 hours.</paragraph>
                  <br/>
                  <paragraph>After consumption of the first liter of MoviPrep solution, the above mixing 
procedure should be repeated with the second pouch A and pouch B to reconstitute 
the second liter of the MoviPrep solution.</paragraph>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="88897de4-a937-447d-8523-fc0dfb0b25e8"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>MoviPrep is available in a carton that contains 4 separate pouches (2 of pouch A 
and 2 of pouch B). Each pouch A contains 100 grams of polyethylene glycol (PEG) 
3350, NF, 7.5 grams of sodium sulfate, USP, 2.691 grams of sodium chloride, USP, 
and 1.015 grams of potassium chloride, USP, plus the following excipients: 
aspartame, NF (sweetener), acesulfame potassium, NF (sweetener), and lemon 
flavoring. Each pouch B contains 4.7 grams of ascorbic acid, USP and 5.9 grams 
of sodium ascorbate, USP.</paragraph>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="b0f2a26a-647c-4399-ba0f-669e3a975ac9"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>MoviPrep is contraindicated in patients who have had a severe hypersensitivity 
reaction to any of its components.</paragraph>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="92d29d30-fb7f-4012-b4fe-d71a16a02f24"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text>
                  <paragraph>MoviPrep should be used with caution in patients with severe 
ulcerative colitis, ileus, gastrointestinal obstruction or perforation, gastric 
retention, toxic colitis, or toxic megacolon</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="emphasis">General</content>
                     </content>
                  </paragraph>
                  <paragraph>Patients with impaired gag reflex and patients prone to regurgitation or 
aspiration should be observed during the administration of MoviPrep.  If a 
patient experiences severe bloating, abdominal distention, or abdominal pain, 
administration should be slowed or temporarily discontinued until the symptoms 
abate. If gastrointestinal obstruction or perforation is suspected, appropriate 
tests should be performed to rule out these conditions before administration of 
MoviPrep®.  </paragraph>
                  <br/>
                  <paragraph>Phenylketonurics: MoviPrep contains phenylalanine – a maximum of 2.33 mg of 
phenylalanine per treatment.</paragraph>
                  <br/>
                  <paragraph>No additional ingredients (e.g., flavorings) should be added to the MoviPrep 
solution.</paragraph>
                  <br/>
                  <paragraph>Since MoviPrep contains sodium ascorbate and ascorbic acid, MoviPrep should 
be used with caution in patients with glucose-6-phosphate dehydrogenase (G-6-PD) 
deficiency especially G-6-PD deficiency patients with an active infection, with 
a history of hemolysis, or taking concomitant medications known to precipitate 
hemolytic reactions.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>5.1 Seizures<paragraph>There have been rare reports of generalized tonic-clonic seizures 
associated with use of polyethylene glycol colon preparation products in 
patients with no prior history of seizures.  The seizure cases were associated 
with electrolyte abnormalities (e.g., hyponatremia, hypokalemia).  The 
neurologic abnormalities resolved with correction of fluid and electrolyte 
abnormalities.  Therefore, MoviPrep should be used with caution in patients 
using concomitant medications that increase the risk of electrolyte 
abnormalities [such as diuretics or angiotensin converting enzyme 
(ACE)-inhibitors] or in patients with known or suspected hyponatremia.  Consider 
performing baseline and post-colonoscopy laboratory tests (sodium, potassium, 
calcium, creatinine, and BUN) in these patients.</paragraph>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ebad6de2-bbb4-4a30-9b28-8143a764239a"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <linkHtml href=""/>6.1 Clinical Studies Experience<paragraph>In the MoviPrep trials, abdominal distension, anal discomfort, 
thirst, nausea, and abdominal pain were some of the most common adverse 
reactions to MoviPrep administration.  Since diarrhea was considered as a part 
of the efficacy of MoviPrep, diarrhea was not defined as an adverse reaction in 
the clinical studies.  Tables 1 and 2 display the most common drug-related 
adverse reactions of MoviPrep and its comparator in the controlled MoviPrep 
trials.</paragraph>
                  <table width="80%" ID="i558ed33d-555f-4fa7-8601-88d8007f204a">
                     <caption>Table 1: The Most Common Drug-Related Adverse Reactions*   (≥ 2%) in the Study of MoviPrep vs. 4 liter Polyethylene Glycol plus Electrolytes Solution</caption>
                     <tbody>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="emphasis">MoviPrep®</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="emphasis">(split dose)</content>
                                 </content>
                              </paragraph>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">N=180</content>
                              </content>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="emphasis">
                                       <content styleCode="bold">
                                          <content styleCode="emphasis">4L PEG + E</content>
                                       </content>
                                    </content>
                                 </content>†<content styleCode="bold">
                                    <content styleCode="emphasis"> <content styleCode="bold">
                                          <content styleCode="emphasis"> </content>
                                       </content>
                                    </content>
                                 </content>
                              </paragraph>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">N=179 </content>
                              </content>    <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>n (% = n/N)<br/>
                           </td>
                           <td>n (% = n/N)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Malaise<br/>
                           </td>
                           <td>35 (19.4)<br/>
                           </td>
                           <td>32 (17.9)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Nausea<br/>
                           </td>
                           <td>26 (14.4)<br/>
                           </td>
                           <td>36 (20.1)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Abdominal pain<br/>
                           </td>
                           <td>24 (13.3)<br/>
                           </td>
                           <td>27 (15.1)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Vomiting<br/>
                           </td>
                           <td>14 (7.8)<br/>
                           </td>
                           <td>23 (12.8)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Upper abdominal pain<br/>
                           </td>
                           <td>10 (5.6)<br/>
                           </td>
                           <td>11 (6.1)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Dyspepsia<br/>
                           </td>
                           <td>5 (2.8)<br/>
                           </td>
                           <td>2 (1.1)<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>*     Drug-related adverse reactions were adverse events that were possibly, probably, 
or definitely related to the study drug.<br/>†     4L PEG + E is 4 liter Polyethylene Glycol plus Electrolytes Solution <br/>
                  <br/>
                  <table width="100%" ID="ice579cc7-df5d-4383-8648-1918cfbfd8d9">
                     <caption>Table 2: The Most Common Drug-Related Adverse Reactions*    (≥ 5%) in the Study of MoviPrep vs. 90 mL Oral Sodium Phosphate Solution</caption>
                     <tbody>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">MoviPrep®</content>
                              </content>
                              <br/>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">(evening-only)</content>
                              </content>
                              <br/>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">(full dose)</content>
                              </content>
                              <br/>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">N=169</content>
                              </content>
                           </td>
                           <td>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">90 mL OSPS</content>
                              </content>†<content styleCode="bold">
                                 <content styleCode="emphasis"/>
                              </content>
                              <br/>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">N=171</content>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>n (% = n/N)<br/>
                           </td>
                           <td>n (% = n/N)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Abdominal distension<br/>
                           </td>
                           <td>101 (59.8)<br/>
                           </td>
                           <td>70 (40.9)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Anal discomfort<br/>
                           </td>
                           <td>87 (51.5)<br/>
                           </td>
                           <td>89 (52.0)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Thirst<br/>
                           </td>
                           <td>80 (47.3)<br/>
                           </td>
                           <td>112 (65.5)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Nausea<br/>
                           </td>
                           <td>80 (47.3)<br/>
                           </td>
                           <td>80 (46.8)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Abdominal paint<br/>
                           </td>
                           <td>66 (39.1)<br/>
                           </td>
                           <td>55 (32.2)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Sleep disorder<br/>
                           </td>
                           <td>59 (34.9)<br/>
                           </td>
                           <td>49 (28.7)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Rigors<br/>
                           </td>
                           <td>57 (33.7)<br/>
                           </td>
                           <td>51 (29.8)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Hunger<br/>
                           </td>
                           <td>51 (30.2)<br/>
                           </td>
                           <td>121 (70.8)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Malaise<br/>
                           </td>
                           <td>45 (26.6)<br/>
                           </td>
                           <td>90 (52.6)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Vomiting<br/>
                           </td>
                           <td>12 (7.1)<br/>
                           </td>
                           <td>14 (8.2)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Dizziness<br/>
                           </td>
                           <td>11 (6.5)<br/>
                           </td>
                           <td>31 (18.1)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Headache<br/>
                           </td>
                           <td>3 (1.8)<br/>
                           </td>
                           <td>9 (5.3)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Hypokalemia<br/>
                           </td>
                           <td>0 (0)<br/>
                           </td>
                           <td>10 (5.8)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Hyperphosphatemia<br/>
                           </td>
                           <td>0 (0)<br/>
                           </td>
                           <td>10 (5.8)<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <content styleCode="bold">
                     <content styleCode="emphasis"/>
                  </content>
                  <br/>*     Drug-related adverse reactions were adverse events that were possibly, probably, 
or definitely related to the study drug. In addition to the recording of 
spontaneous adverse events, patients were also specifically asked about the 
occurrence of the following symptoms: shivering, anal irritations, abdominal 
bloating or fullness, sleep loss, nausea, vomiting, weakness, hunger sensation, 
abdominal cramps or pain, thirst sensation, and dizziness.<br/>†     OSPS is Oral Sodium Phosphate Solution<br/>
                  <br/>
                  <paragraph>Isolated cases of urticaria, rhinorrhea, dermatitis, and anaphylactic 
reaction have been reported with PEG-based products and may represent allergic 
reactions.</paragraph>
                  <paragraph>Published literature contains isolated reports of serious adverse events 
following the administration of PEG-based products in patients over 60 years of 
age. These adverse events included upper gastrointestinal bleeding from a 
Mallory-Weiss tear, esophageal perforation, asystole, and acute pulmonary edema 
after aspirating the PEG-based preparation.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>6.2 Postmarketing Experience<paragraph>In addition to adverse events reported from clinical trials, the 
following adverse events have been identified during post-approval use of 
MoviPrep. Because they are reported voluntarily from a population of unknown 
size, estimates of frequency cannot be made. These events have been chosen for 
inclusion due to either their seriousness, frequency of reporting or causal 
connection to MoviPrep, or a combination of these factors. </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="emphasis">General:</content>
                     </content> Hypersensitivity 
reactions including anaphylaxis, rash, urticaria, lip and facial swelling, 
dyspnea, chest tightness and throat tightness.</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="57151e91-118f-4547-9a90-7bbb0aee1265"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7  DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Oral medication administered within 1 hour of the start of administration of 
MoviPrep may be flushed from the gastrointestinal tract and the medication may 
not be absorbed.</paragraph>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="95a49e3b-6200-46cb-9843-fc6b5f1c01b8"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8  USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <linkHtml href=""/>8.1 Pregnancy: Teratogenic Effects<paragraph>Pregnancy Category C. Animal reproduction studies have not been 
performed with MoviPrep.  It is also not known if MoviPrep can cause fetal harm 
when administered to a pregnant woman or can affect reproductive capacity. 
MoviPrep should be given to a pregnant woman only if clearly needed.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>8.3 Nursing Mothers<paragraph>Because many drugs are excreted in human milk, caution should be 
exercised when MoviPrep is administered to a nursing woman.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>8.4 Pediatric Use<paragraph>The safety and effectiveness of MoviPrep in pediatric patients 
has not been established.<br/>
                  </paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>8.5 Geriatric Use<paragraph>Of the 413 patients in clinical studies receiving MoviPrep, 91 
(22%) patients were aged 65 or older, while 25 (6%) patients were over 75 years 
of age.  No overall differences in safety or effectiveness were observed between 
geriatric patients and younger patients, and other reported clinical experience 
has not identified differences in responses between geriatric patients and 
younger patients, but greater sensitivity of some older individuals cannot be 
ruled out.</paragraph>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="4f106790-dda4-42ac-94eb-43a924e058fd"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10  OVERDOSAGE</title>
               <text>
                  <paragraph>There have been no reported cases of overdose with MoviPrep.  Purposeful or 
gross accidental ingestion of more than the recommended dose of MoviPrep might 
be expected to lead to severe electrolyte disturbances, including hyponatremia 
and/or hypokalemia, as well as dehydration and hypovolemia, with signs and 
symptoms of these disturbances. The patient who has taken an overdose should be 
monitored carefully, and treated symptomatically for complications until stable.</paragraph>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="faa339dd-d866-4c16-87cb-37559f84a305"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>MoviPrep® consists of 4 separate pouches (2 of pouch A and 2 of pouch B) 
containing white to yellow powder for reconstitution.  Each pouch A contains 100 
grams of polyethylene glycol (PEG) 3350, NF, 7.5 grams of sodium sulfate, USP, 
2.691 grams of sodium chloride, USP, and 1.015 grams of potassium chloride, USP, 
plus the following excipients: aspartame, NF (sweetener), acesulfame potassium, 
NF (sweetener), and lemon flavoring. Each pouch B contains 4.7 grams of ascorbic 
acid, USP and 5.9 grams of sodium ascorbate, USP.  When 1 pouch A and 1 pouch B 
are dissolved together in water to a volume of 1 liter, MoviPrep (PEG-3350, 
sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and 
ascorbic acid) is an oral solution having a lemon taste.<br/> <br/>The entire, 
reconstituted, 2-liter MoviPrep colon preparation contains 200 grams of 
PEG-3350, 15 grams of sodium sulfate, 5.38 grams of sodium chloride, 2.03 grams 
of potassium chloride, 9.4 grams of ascorbic acid, and 11.8 grams of sodium 
ascorbate plus the following excipients: aspartame (sweetener), acesulfame 
potassium (sweetener), and lemon flavoring.</paragraph>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="522339ed-5f70-43cf-8af3-f72b9529100e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12  CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>MoviPrep produces a watery stool leading to cleansing of the 
colon. The osmotic activity of polyethylene glycol 3350, sodium sulfate, sodium 
chloride, potassium chloride, sodium ascorbate, and ascorbic acid, when taken 
with 1 liter of additional clear fluid, usually results in no net absorption or 
excretion of ions or water. </paragraph>
                  <br/>
                  <paragraph>The pharmacokinetics of MoviPrep have not been studied in patients with renal 
or hepatic insufficiency.</paragraph>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="8832224c-f982-4cd1-91ac-56405b812a86"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13  NONCLINICAL TOXICOLOGY</title>
               <text>
                  <linkHtml href=""/>13.1 Carcinogenesis, Mutagenesis, Impairment of 
Fertility<paragraph>Long-term studies in animals to evaluate the carcinogenic 
potential have not been performed with MoviPrep®.  Studies to evaluate potential 
for impairment of fertility or mutagenic potential have not been performed with 
MoviPrep®.</paragraph>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="257111bc-9542-47dc-ae47-3c9adc4c3478"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14  CLINICAL STUDIES</title>
               <text>
                  <paragraph>The colon cleansing efficacy and safety of MoviPrep was evaluated 
in two randomized, actively-controlled, multi-center, investigator-blinded, 
phase 3 trials in patients scheduled to have an elective colonoscopy. </paragraph>
                  <br/>
                  <paragraph>In the first study, patients were randomized to one of the following two 
colon preparation treatments:  1) 2 liters of MoviPrep with 1 additional liter 
of clear fluid split into two doses (during the evening before and the morning 
of the colonoscopy) and 2) 4 liters of polyethylene glycol plus electrolytes 
solution (4L PEG + E) split into two doses (during the evening before and the 
morning of the colonoscopy).  Patients were allowed to have a morning breakfast, 
a light lunch, clear soup and/or plain yogurt for dinner.  Dinner had to be 
completed at least one hour prior to initiation of the colon preparation 
administration.  </paragraph>
                  <br/>
                  <paragraph>The primary efficacy endpoint was the proportion of patients with effective 
colon cleansing as judged by blinded gastroenterologists on the basis of 
videotapes recorded during the colonoscopy. <br/>The blinded gastroenterologists 
graded the colon cleansing twice (during introduction and withdrawal of the 
colonoscope) and the poorer of the two assessments was used in the primary 
efficacy analysis.  </paragraph>
                  <br/>
                  <paragraph>The efficacy analysis included 308 adult patients who had an elective 
colonoscopy.  Patients ranged in age from 18 to 88 years old (mean age about 59 
years old) with 52% female and 48% male patients.  Table 3 displays the results.</paragraph>
                  <table width="100%" ID="i5b00a400-f423-4441-8be1-520ff67a1f5e">
                     <caption>Table 3: Effectiveness of Overall Colon Cleansing in the Study of MoviPrep vs 4 Liter Polyethylene Glycol plus Electrolytes Solution</caption>
                     <tbody>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="emphasis">Responders</content>
                                 </content>
                              </paragraph>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">A</content>
                              </content>*<content styleCode="bold">
                                 <content styleCode="emphasis">   or B</content>
                              </content>†<content styleCode="bold">
                                 <content styleCode="emphasis"> </content>
                              </content>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">  (%)</content>
                              </content>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">C</content>
                              </content>‡<content styleCode="bold">
                                 <content styleCode="emphasis">   (%)</content>
                              </content>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">D</content>
                              </content>§<content styleCode="bold">
                                 <content styleCode="emphasis">   (%)</content>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="emphasis">MoviPrep®</content>
                                 </content>
                              </paragraph>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">    (N=153)</content>
                              </content>
                              <br/>
                           </td>
                           <td>88.9<br/>
                           </td>
                           <td>9.8<br/>
                           </td>
                           <td>1.3<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="emphasis">
                                       <content styleCode="bold">
                                          <content styleCode="emphasis">4L PEG + E</content>
                                       </content>
                                    </content>
                                 </content>¶<content styleCode="bold">
                                    <content styleCode="emphasis"> <content styleCode="bold">
                                          <content styleCode="emphasis"> </content>
                                       </content>
                                    </content>
                                 </content>
                              </paragraph>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">    (N=155)</content>
                              </content>
                              <br/>
                           </td>
                           <td>94.8<br/>
                           </td>
                           <td>4.5<br/>
                           </td>
                           <td>0.6<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>*     A: colon empty and clean or presence of clear liquid, but easily removed by 
suction <br/>†     B: brown liquid or semisolid remaining amounts of stool, fully removable by 
suction or displaceable, thus allowing a complete visualization of the gut 
mucosa <br/>‡     C: semisolid amounts of stool, only partially removable with a risk of 
incomplete visualization of the gut mucosa <br/>
                  <content styleCode="bold">
                     <content styleCode="emphasis"/>
                  </content>§     D: semisolid or solid amounts of stool; consequently colonoscopy incomplete or 
needed to be terminated. 4 L PEG+E's responder rate was not significantly higher 
than MoviPrep's responder rate.<br/>¶     4L PEG + E is 4 Liter Polyethylene Glycol plus Electrolytes Solution<br/>
                  <br/>
                  <paragraph>In the second study, patients were randomized to one of the following two 
colon preparation treatments:  1) 2 liters of MoviPrep with 1 additional liter 
of clear fluid in the evening prior to the colonoscopy and 2) 90 mL of oral 
sodium phosphate solution (90 mL OSPS) with at least 2 liters of additional 
clear fluid during the day and evening prior to the colonoscopy.  Patients 
randomized to MoviPrep therapy were allowed to have a morning breakfast; a light 
lunch; and clear soup and/or plain yogurt for dinner.  Dinner had to be 
completed at least one hour prior to initiation of the colon preparation 
administration.<br/> <br/>The primary efficacy endpoint was the proportion of 
patients with effective colon cleansing as judged by the colonoscopist and one 
blinded gastroenterologist (on the basis of videotapes recorded during the 
colonoscopy).  In case of a discrepancy between the colonoscopist and the 
blinded gastroenterologist, a second blinded gastroenterologist made the final 
efficacy determination.</paragraph>The efficacy analysis included 280 adult patients who had an elective 
colonoscopy.  Patients ranged in age from 21 to 76 years old (mean age about 53 
years old) with 47% female and 53% male patients.  Table 4 displays the results.<br/>
                  <table width="100%" ID="ie127cd5c-de17-4aee-885a-a5c288b2575d">
                     <caption>Table 4: Effectiveness of Overall Colon Cleansing in the Study of MoviPrep vs 90mL Oral Sodium Phosphate Solution </caption>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">
                                 <content styleCode="emphasis"/>
                              </content>
                              <br/>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="emphasis">Responders</content>
                                 </content>
                              </paragraph>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">A</content>
                              </content>*<content styleCode="bold">
                                 <content styleCode="emphasis"> or B</content>
                              </content>†<content styleCode="bold">
                                 <content styleCode="emphasis"> (%)</content>
                              </content>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">C</content>
                              </content>‡<content styleCode="bold">
                                 <content styleCode="emphasis"> (%)</content>
                              </content>
                           </td>
                           <td>D§ (%)</td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="emphasis">MoviPrep®</content>
                                 </content>
                              </paragraph>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">(N=137)</content>
                              </content>
                           </td>
                           <td>73.0<br/>
                           </td>
                           <td>23.4<br/>
                           </td>
                           <td>3.6</td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="emphasis">90 mL OSPS</content>
                                 </content>¶ </paragraph>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">(N=143)</content>
                              </content>
                              <br/>
                           </td>
                           <td>64.4<br/>
                           </td>
                           <td>29.4<br/>
                           </td>
                           <td>6.3<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
                  <br/>*     A: empty and clean or clear liquid (transparent, yellow, or green) <br/>†     B: brown liquid or semisolid remaining small amounts of stool, fully removable 
by suction or displaceable allowing a complete visualization of the underlying 
mucosa <br/>‡     C: semi solid only partially removable/displaceable stools; risk of incomplete 
examination of the underlying mucosa <br/>§     D: heavy and hard stool making the segment examination uninterpretable and, 
consequently, the colonoscopy needed to be terminated <br/>¶     <br/>OSPS is Oral Sodium Phosphate Solution <br/>MoviPrep's responder rate was not significantly higher than OSPS's responder 
rate.<br/>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="92fa19f5-2568-40b4-a5bd-438d3a0bc63c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16  HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>MoviPrep® is supplied in powdered form.  MoviPrep is administered 
as an oral solution after reconstitution. </paragraph>
                  <paragraph>NDC 54868-5890-0, MoviPrep, single use carton. <br/>
                     <br/>
                  </paragraph>
                  <paragraph>Each carton contains a disposable container for reconstitution of MoviPrep® 
and an inner carton containing 4 pouches (2 of pouch A and 2 of pouch 
B).</paragraph>
                  <br/>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="emphasis">Rx only</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="emphasis">STORAGE</content>
                     </content>
                     <br/>
                     <br/>Store 
carton/container at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). When 
reconstituted, store upright and keep solution refrigerated. Use within 24 
hours.</paragraph>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="530d5fee-58a9-42dc-ba3e-ea723ee89de4"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17  PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Important Precautions Regarding MOVIPREP</paragraph>
                  <paragraph>MoviPrep produces a watery stool which cleanses the colon before 
colonoscopy.  It is recommended that patients receiving MoviPrep be advised to 
adequately hydrate before, during, and after the use of MoviPrep. Patients may 
have clear soup and/or plain yogurt for dinner, finishing the evening meal at 
least one hour prior to the start of MoviPrep treatment.  No solid food should 
be taken from the start of MoviPrep treatment until after the 
colonoscopy.</paragraph>
                  <br/>
                  <paragraph>What Patients Should Know About Adverse Reactions</paragraph>
                  <paragraph>The first bowel movement may occur approximately 1 hour after the start of 
MoviPrep administration. Abdominal bloating and distention may occur before the 
first bowel movement. If severe abdominal discomfort or distention occurs, stop 
drinking temporarily or drink each portion at longer intervals until these 
symptoms disappear.</paragraph>
                  <br/>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="emphasis">
                           <content styleCode="bold">
                              <content styleCode="emphasis">Manufactured by:</content>
                           </content>
                           <br/>
                        </content>
                     </content>Norgine 
B.V.<br/>Hogehilweg 7<br/>1101 CA Amsterdam Zuidoost<br/>Netherlands </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="emphasis">
                           <content styleCode="bold">
                              <content styleCode="emphasis">For:</content>
                           </content>
                           <br/>
                        </content>
                     </content>Salix Pharmaceuticals, 
Inc.<br/>Morrisville, NC 27560</paragraph>
                  <paragraph>© 2006 Salix Pharmaceuticals, Inc.<br/>VENART xxx-x/June 09</paragraph>
                  <paragraph>Product protected by U.S. Patent No. 7169381 and other pending applications</paragraph>
               </text>
               <effectiveTime value="20091130"/>
            </section>
         </component>
         <component>
            <section>
               <id root="edbc089a-955a-4665-b9ba-1b0c0cba747d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="emphasis">
                           <content styleCode="bold">
                              <content styleCode="emphasis">MoviPrep®</content>
                           </content>
                           <br/>
                        </content>
                     </content>(PEG-3350, Sodium 
Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid 
for Oral Solution) </paragraph>
                  <paragraph>Phenylketonurics:<br/>contains phenylalanine – a maximum of 2.33 mg per course 
of treatment.</paragraph>
                  <paragraph>This carton contains<br/>One container for reconstitution of <content styleCode="bold">
                        <content styleCode="emphasis">MoviPrep®</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
               </text>
               <effectiveTime value="20091130"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM1">
                     <text>image of package label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="package label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>